The second quarter of 2024 marked several milestones towards achieving market approval in the U.S. Notably, the company’s medical device received CB certification, indicating that Neola®meets the required technical safety standards. Clinical trials are now on the horizon, with further updates expected in the fall.
Watch CEO Hanna Sjöström and CTO Sara Bergsten discuss Neola Medical’s newly released Q2 report in the BioStock Studio below: